{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:10:34Z","timestamp":1778267434716,"version":"3.51.4"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The placebo effect is a well-recognized phenomenon in human medicine; in contrast, little information exists on the effect of placebo administration in veterinary patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>Nonpharmacologic therapeutic effects play a role in response rates identified in canine epilepsy trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Thirty-four dogs with epilepsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Meta-analysis of the 3 known prospective, placebo-controlled canine epilepsy trials. The number of seizures per week was compiled for each dog throughout their participation in the trial. Log-linear models were developed to evaluate seizure frequency during treatment and placebo relative to baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-two of 28 (79%) dogs in the study that received placebo demonstrated a decrease in seizure frequency compared with baseline, and 8 (29%) could be considered responders, with a 50% or greater reduction in seizures. For the 3 trials evaluated, the average reduction in seizures during placebo administration relative to baseline was 26% (P= .0018), 29% (P= .17), and 46% (P= .01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>A positive response to placebo administration, manifesting as a decrease in seizure frequency, can be observed in epileptic dogs. This is of importance when evaluating open label studies in dogs that aim to assess efficacy of antiepileptic drugs, as the reported results might be overstated. Findings from this study highlight the need for more placebo-controlled trials in veterinary medicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1939-1676.2009.0407.x","type":"journal-article","created":{"date-parts":[[2009,11,11]],"date-time":"2009-11-11T12:40:01Z","timestamp":1257943201000},"page":"166-170","source":"Crossref","is-referenced-by-count":85,"title":["Placebo Effect in Canine Epilepsy Trials"],"prefix":"10.1093","volume":"24","author":[{"given":"K.R.","family":"Mu\u00f1ana","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, North Carolina State University Department of Clinical Sciences, , Raleigh, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Zhang","sequence":"additional","affiliation":[{"name":"North Carolina State University Department of Statistics, , Raleigh, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.E.","family":"Patterson","sequence":"additional","affiliation":[{"name":"University of Minnesota Department of Veterinary Clinical Science, , St Paul, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,1,1]]},"reference":[{"key":"2026020523265443500_b1","doi-asserted-by":"crossref","first-page":"992","DOI":"10.2460\/javma.1999.215.07.992","article-title":"The placebo effect in animals","volume":"215","author":"McMillan","year":"1999","journal-title":"J Am Vet Med Assoc"},{"key":"2026020523265443500_b2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev.med.47.1.193","article-title":"Harnessing the power of the placebo effect and renaming it \u201cremembered wellness\u201d","volume":"47","author":"Benson","year":"1996","journal-title":"Annu Rev Med"},{"key":"2026020523265443500_b3","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1001\/jama.1955.02960340022006","article-title":"The powerful placebo","volume":"159","author":"Beecher","year":"1955","journal-title":"J Am Med Assoc"},{"key":"2026020523265443500_b4","first-page":"375","article-title":"The power of nonspecific effects in healing","volume":"13","author":"Roberts","year":"1993","journal-title":"Implication for psychosocial and biological treatments"},{"key":"2026020523265443500_b5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1751-0147-46-57","article-title":"Stratification, blinding and placebo effect in a randomized, double blind placebo-controlled clinical trial of gold bead implantation in dogs with hip dysplasia","volume":"46","author":"J\u00e6ger","year":"2005","journal-title":"Acta Vet Scand"},{"key":"2026020523265443500_b6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2460\/javma.2002.221.977","article-title":"Use of vagal nerve stimulation as a treatment for refractory epilepsy in dogs","volume":"221","author":"Mu\u00f1ana","year":"2002","journal-title":"J Am Vet Med Assoc"},{"key":"2026020523265443500_b7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2307\/2531248","article-title":"Longitudinal data analysis for discrete and continuous outcomes","volume":"42","author":"Zeger","year":"1986","journal-title":"Biometrics"},{"key":"2026020523265443500_b8","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S1525-5050(02)00531-0","article-title":"Magnitude of the placebo effect in randomized trials of antiepileptic agents","volume":"3","author":"Burneo","year":"2002","journal-title":"Epilepsy Behav"},{"key":"2026020523265443500_b9","first-page":"590","article-title":"New antiepileptic drugs","volume":"40","author":"Cramer","year":"1999","journal-title":"Comparison of key clinical trials"},{"key":"2026020523265443500_b10","first-page":"413","article-title":"Placebo","volume":"12","author":"Ernst","year":"2007","journal-title":"New insights into an old enigma"},{"key":"2026020523265443500_b11","first-page":"59","article-title":"Regression to the mean","volume":"11","author":"Morton","year":"2005","journal-title":"Treatment effect without the intervention"},{"key":"2026020523265443500_b12","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200105243442106","article-title":"Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment","volume":"344","author":"Hr\u00f3bjartsson","year":"2001","journal-title":"N Engl J Med"},{"key":"2026020523265443500_b13","first-page":"881","article-title":"Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy","volume":"159","author":"Platt","year":"2006","journal-title":"Vet Rec"},{"key":"2026020523265443500_b14","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1751-0813.2005.tb13269.x","article-title":"Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent","volume":"83","author":"Govendir","year":"2005","journal-title":"Aus Vet J"},{"key":"2026020523265443500_b15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5326\/0400285","article-title":"Zonisamide therapy for refractory idiopathic epilepsy in dogs","volume":"40","author":"Dewey","year":"2004","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020523265443500_b16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1748-5827.2006.00290.x","article-title":"Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs","volume":"48","author":"Von Klopmann","year":"2007","journal-title":"J Sm Anim Pract"},{"key":"2026020523265443500_b17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.tvjl.2007.03.002","article-title":"The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs","volume":"176","author":"Volk","year":"2008","journal-title":"Vet J"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1939-1676.2009.0407.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/24\/1\/166\/66654464\/j.1939-1676.2009.0407.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/24\/1\/166\/66654464\/j.1939-1676.2009.0407.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T04:27:02Z","timestamp":1770352022000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/24\/1\/166\/8447302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1939-1676.2009.0407.x","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,1]]},"published":{"date-parts":[[2010,1,1]]}}}